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Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
Advances in Drug Therapy:  
Alternative Treatments for the Control  
of Motor Fluctuations and Dyskinesias  
José Matías Arbelo González and Rocío Malo de Molina Zamora 
Insular of Gran Canaria Universitary Hospital, 
Spain 
1. Introduction  
The treatment of Parkinson´s Disease (PD) remains largely symptomatic and it controls 
effectively motor symptoms of the disease for some years. This is a treatment that is 
considered basically substitute, which only acts on the nigrostriatal pathway but does not 
provide adequate plasma levels 24 hours a day in most cases. As a result, conventional 
medication, especially levodopa, produces pulsatile stimuli that with the progression of the 
disease is associated with the development of motor complications (Markham & Diamond, 
1986). 
In recent years new formulations and alternative therapies (dopamine receptor agonists 
extended release, rotigotine patch, continuous infusion of apomorphine and continuous 
duodenal infusion of Duodopa) have been introduced in order to avoid pulsatile 
stimulation and thus prevent the "peaks " and "valleys" and achieve continuous 
dopaminergic stimulation to avoid, reduce or control the motor fluctuations and 
dyskinesias. Thus concept of continuous dopaminergic stimulation is born, which is not 
intended to restore modulatory physiological  role exerted by dopamine on striatal 
function but to explain the benefits of using drugs that provide a more uniform and 
consistent  dopamine stimulation, which has proven to be most appropriate and in 
practice more beneficial than traditional treatments. This review focuses on the treatment 
for symptomatic control of Parkinson's disease and complications from chronic treatment, 
the usefulness of new dopamine agonists and the beneficial effect of Duodopa as a 
possible alternative in the treatment of advanced PD compared with subcutaneous 
apomorphine infusion or deep brain stimulation of the subthalamic nucleus, this latter 
effective to control of motor complications but applicable to a very selective population 
with no cognitive or behavioral complications. 
It is clear that oral Levodopa combined with peripheral inhibitory amino-acid decarboxylase 
remains still the gold standard in the treatment of PD 40 years later after their use by 
Cotzias. However, chronic treatment with levodopa (LD) is related to the onset of motor 
complications in form of fluctuations in the response with wearing-off phenomenon and 
dyskinesia, which may occur after 3 to 5 years after the start of the LD (Markham & 
Diamond, 1986; Marsden, 1994). This variability in motor response is correlated with the 
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fluctuation in plasma concentration of LD (related to oral intermittent delivery and irregular 
gastric emptying) and consequently with the level of pulsatile stimulation of dopamine 
receptors in the striatum (De la Fuente-Fernández et al., 2001). As the disease progresses, the 
therapeutic window is narrowed in such a way that reduces the response time "on" increases 
the off time and is easily reached the threshold for dyskinesias. Motor complications and the 
also increasingly important non-motor complications are being accentuated with the 
worsening of the disease and therefore impacts the quality of life of patients (Dodel et al., 
2001; Clarke et al., 2002; Witjas et al., 2002). 
2. Medical treatment 
2.1 Dopamine agonist  
Different strategies have been developed to achieve greater continuous dopaminergic 
stimulation with the sole purpose of delay, reduce or avoid fluctuations (Holloway et al., 
2004;  Rascol et al., 2006). These options include the administration of dopamine agonists 
(DA) which have proven effective in both the early stage of the disease and in the 
moderately advanced stage, improving motor symptoms and delaying the onset of motor 
complications resulting from the use of LD (Hauser et al., 2007). However, one of the biggest 
problems of AD has been the need for a slow titration to ensure good tolerance and 
therefore a delay in obtaining clinical benefits. The new formulations of extended-release 
agonists provide the advantage of producing a continuous release ensuring sustained 
absorption over 24 hours and reducing plasma fluctuations (Tompson & Vearer, 2007). 
Certainly in the treatment of PD, non-ergot dopamine agonists are considered first-line 
therapy in a substantial proportion of patients. 
2.1.1 Ropinirole prolonged-release (RPR)  
Perhaps one of the most interesting contributions was the fact that in a recent study, 
prolonged release ropinirole has shown good tolerance with higher starting dose that 
immediate release ropinirole and this results in a faster titration (Stocchi et al., 2008) and 
better clinical response significantly in a period of 4 weeks compared with placebo (Herh et 
al., 2010). It has been proven non-inferiority of therapeutic response with respect to the 
formulation of immediate response in monotherapy and in early stages of the disease 
(Stocchi et al., 2008). Its effectiveness has also been tested in advanced stage patients which 
not adequately controlled with levodopa, in a randomized, double-blind, placebo for 24 
weeks, with a significant reduction in off time of 2.1 hours against 0.3 hours compared to 
placebo group, and improved quality of life PDQ (Pahwa et al., 2007). Due to the effect 
observed for 24 hours with this new formulation, several aspects of sleep and nocturnal 
symptoms improve. As a side effect, RPR causes sleepiness and fatigue which remain 
practically the same percentage as the immediate release formulation. Finally it is expected a 
better adherence to the administration once a day. 
2.1.2 Delayed pramipexole  
Another interesting alternative in the no ergot-AD group is the new long acting formulation 
of pramipexole, administered once daily to maintain stable levels 24 hours. It has proven 
effective in improving parkinsonian symptoms in the early stages of the disease and in 
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advanced patients with motor fluctuations resulting in a decrease in off time compared to 
placebo. No differences in the tolerance respect the immediate release form and the side 
effects are also comparable (Poewe, 2008; Schapira, 2007). Perhaps the most important 
indication when compared to immediate-release pramipexole is the fact that it improves 
treatment adherence in PD. 
2.1.3 Rotigotina   
Rotigotina is the only non-ergot D3/D2/D1 AD with a formulation which allows for 
transdermal administration which is very important when it is necessary to reduce the oral 
medication.  Its bioavailability is 37%, its active ingredient is released into the skin during 24 
hours (Chen et al., 2009), reaching concentrations that are stable for 24 hours (Chen et al., 
2009; Reichmann, 2009) and it has a low risk of accumulation due to its half-life of about 5-7 
hours. It is administered by a transdermal patch of silicon and due to its lipophilic, follicular 
and eccrine properties rotigotine penetrates the skin by transcellular and intercellular 
pathways, providing a constant supply. It is rapidly metabolized and eliminated by renal 
and hepatic via and it avoids first-pass effect. 
Studies in early stages of the disease support the efficacy compared with other agonists. In 
addition there is a better tolerance in relation to classical complications such as drowsiness, 
orthostatic hypotension and hallucinations, but on the other hand must be taken into 
account cutaneous reactions (The Parkinson Study Group, 2003; Giladi et al., 2007). It has 
also shown efficacy in advanced stages compared with oral agonists (Poewe et al., 2007), 
facilitating its administration when complications occur, such as dysphagia, alteration of 
intestinal transit and when the patient requires  absolute diets such as in preoperative and 
postoperative situations (Korczyn et al., 2007.) Another interesting aspect is its possible 
effect on non-motor disorders of PD, mainly on the improvement of quality of sleep by 
improving other aspects such as akinesia, dystonia, nocturia and nocturnal cramps, without 
worsening daytime sleepiness (Giladi et al., 2006). RECOVER study results support the 
improvement of sleep disorders by PDSS scale and UPDRS-III scores on awakening 
(Trenkwalder et al., 2009).  
2.1.4 Apomorphine  
Apomorphine was the first dopamine receptor agonist used to treat Parkinson's disease over 
60 years ago (Schwab et al., 1951; Cotzias et al., 1970). It is an  a short-term agonist dopamine 
that direct acts on D1 and D2 receptors (Kempster et al., 1990; Colosimo et al., 1996), with 
clinical antiparkinsonian action very powerful, equivalent to the LD, both qualitatively and 
quantitatively. Apomorphine has  a rapid absorption (C max 20 minutes) and a half-life of 
43 minutes, which is consistent with its rapid onset of action with evident effects after 15-20 
minutes of subcutaneous administration. 
The efficacy of intermittent subcutaneous apomorphine has been confirmed in several 
studies (Poewe & Wenning, 2000; Pfeiffer et al., 2007). Moreover, the effectiveness of 
continous subcutaneous apomorphine infusion apomorphine (CSAI) has been evaluated 
both in monotherapy as in addition to levodopa treatment in advanced PD. Several 
clinical studies support the CSAI to control motor fluctuations poorly controlled by 
conventional oral route. Apomorphine generally leads to an improvement on the time off 
between 50-80% and improves dyskinesias associated with LD (Katzenschlager et al., 
2005). While the improvement in off time is constant in all studies, the improvement of 
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dyskinesias is less significant and is related to the reduction of the dose of LD. Moreover 
apomorphine in monotherapy can be achieved only at very high doses, usually above 100 
mg / day, which are poorly tolerated by patients. Therefore most require a combination 
with oral LD, which in fact does not eliminate the effect of pulsatility and prevent the 
benefit on dyskinesia (Antonini & Tolosa, 2009). From the practical point of view we 
recommend pre-medicating the patient with domperidone at least three days before the 
start to prevent peripheral dopaminergic effects and alleviate or eliminate the effect of 
nausea and vomiting. Oral AD medication should be discontinued and start the infusion 
of apomorphine with 1 mg / hour maintaining the same dose of L-Dopa. The dose of 
apomorphine should be gradually increased depending on tolerance at the same time it 
should be gradually reduced the dose of L-dopa to reduce dyskinesias and if possible 
remove it completely. 
However, the CSAI is not free of side effects, the most constant are the presentation of 
subcutaneous nodules (70-80%), sedation and somnolence (23%), nausea and vomiting 
(10%), renal failure (6%), positive Coombs test (6%) and orthostatic hypotension (5%). The 
adecuate local hygiene and daily change of subcutaneous injection site are important 
measures to prevent panniculitis. (Antonini et al., 2009) 
There is no clear definition of the best candidates. They are usually advanced PD patients 
with good motor response to L-dopa but inadequately controlled on oral medication and 
who have motor fluctuations. Patients with cognitive impairment, elderly, orthostatic 
hypotension, severe systemic disease and a history of dopaminergic psychosis must be 
excluded. 
In a study of continous subcutaneous apomorphine infusion realized in Spain from 2003 to 
March 2007 in 35 tertiary care hospital centers with a recruitment of 166 patients of whom 82 
patients were selected with on-off fluctuations (96%), dyskinesias (48%), whose main 
objective was to improve the fluctuations, while the dyskinesias associated with L-dopa was 
not the main purpose unless very severe dyskinesias, with apomorphine dose continuous 
infusion between 35 mg and 160 mg/day for an average 14 hours per day  the following  
results were found statistically significant: improvement in total UPDRS and motor UPDRS, 
reduction in the number of off hour per day and number of off episodes per day, reduction 
in dyskinesias and improvement in balance of gait, reduction in total dose of oral 
antiparkinsonian medication. Only 3 patients received CSAI in monotherapy, while only 20 
needed oral L-dopa mainly in a morning standard dose or in a controlled release Ldopa at 
night. Most patients had side effects; the most common were subcutaneous nodules. 
Neuropsychiatric side effects were frequent and the most common have been hallucinations, 
hypersexuality, confusional state and other complications such as sedation, drowsiness, 
nausea, orthostatic hypotension and hemolytic anemia. About duration of the 82 patients 
studied, 27 had been received CSAI for over two years and 9 patients for at least 4 years 
(García Ruiz et al., 2008). 
In conclusion CSAI is a non aggressive, easy to perform and relatively easy to control 
technique. Certainly the patient and family should have some skill in handling the device 
and must maintain scrupulous hygiene. This confirms once again that CSAI is effective for 
control of advanced PD with severe fluctuations that are not well controlled with 
conventional oral medication. 
However, the real impact of CSAI in advanced PD is still a subject for debate. 
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2.2 Entacapone  
Another option is the use of inhibition of catechol-O-methyltransferase (ICOMT), 
entacapone. It has been noted that its administration increases the levodopa half-life of 
over 85% and decreases its metabolite 3-O-methyldopa plasma concentrations (Nutt et al., 
1994). However, we must consider that it may have a heterogeneous effect in patients. 
Thus patients with low COMT activity would obtain a low optimal effect, while patients 
with high activity would obtain better clinical effect but also increase risk of adverse 
effects. This is due to the existence of polymorphisms of the COMT, which enzyme 
activity is variable in the population and is related to the substitution of valine for 
methionine at codon 158 (Syvanen et al., 1997). In Several randomized controlled trial, in 
which we evaluated the adjuvant effect of entacapone versus placebo in patients with PD 
and motor complications, there is a significant reduction in off time, improved on time, 
decrease the dose of levodopa. Its main side effect is the presentation of nausea, vomiting 
and diarrhea, as well as dyskinesias that can be easily controlled with levodopa reduction 
(Pahwa et al., 2006). Their use has led to the hypothesis that if a continuous release of LD 
is gotten may reduce the risk of motor complications. This could be possible with the 
combination of LD with entacapone, an inhibitor of catechol-0-methyltransferase. This 
hypothesis recently led STRIDE-PD (Stalevo Reduction in Dyskinesia Evaluation), a 
multicenter, double-blind, randomized, flexible dose of levodopa (200-1000 mg), with 
monitoring between 134 and 208 weeks in 747 patients that require initiation of LD, in 
four doses per day, establishing two groups (LD and LD + entacapone stratified by use of 
AD at the beginning), which results did not support the early initiation of LD + 
entacapone reduces the risk of complications and delays the presentation of dyskinesias. 
There are an increase the risk and higher frequency of dyskinesias in the subgroup of 
patients taking AD, whereas in the subgroup not taking agonists there are no difference in 
the time of onset of this complication. The wearing-off occurs more frequently in the LD 
group than in the LD + entacapone group, but the start time of wearing-off was similar in 
both groups. This result was not affected by the use of agonists (Stocchi et al., 2010). 
2.3 Duodopa  
Duodopa is a recent use drug. It is a suspension of micronized levodopa in a 
methylcellulose thickener gel, which was initially used as compassionate use, but since 2004 
its indication was approved in several European countries in advanced PD. At this stage of 
the disease, levodopa infusion via the gut is an important alternative because it reduces the 
fluctuations of plasma LD levels and therefore improves the motor response unresponsive 
to conventional oral therapy (Nyholm et al., 2008), however it should be subject to selection 
criteria (table 1). 
 
 - PD with disabling motor fluctuations (ON_OFF phenomena)  
 - Lack of efficacy of conventional treatments 
 - Response to levodopa, preferably with some quality ON periods 
 - Preferably with no cognitive impairment or mild cognitive impairment 
 - Without psychiatric or behavioral disorders 
 - No age limit (good condition) 
 - Good family or social support 
Table 1. Choosing the right candidate 
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2.3.1 Infusion intrayeyunal of duodopa: control of motor and non motor symptoms  
Intrayeyunal infusion of gel levodopa/carbidopa (Duodopa) may represent the more 
physiological treatment of motor complications in advanced PD using the concept of 
continuous dopaminergic stimulation observed LD plasma stability compared with oral 
therapy. Numerous studies have shown a reduction in off-time, an increase in on-time, 
reduction the severity of dyskinesias and their duration, including patients with deep brain 
stimulation therapy whose results have been insufficient or ineffective (Antonini et al., 
2008). Compared to other options such as subcutaneous apomorphine infusion and DBS 
surgery, monotherapy with duodopa is usually achieved, avoiding therefore other pulsatile 
administration of additional medications (Antonini, 2007). DBS will not be discussed in this 
chapter. 
However in advanced PD, motor symptoms are not the only major disruption but also the 
existence of non-motor symptoms (NMS) are often refractory to conventional treatment and 
contributes to a deterioration in the quality of life, stress and hospitalizations (Chaudhuri et 
al., 2006; Martínez-Martín et al., 2007) so in recent years have gained considerable 
recognition for the impact of these symptoms on quality of life (Chaudhuri et al., 2008). 
Non-motor signs of PD can be quantified using the non-motor symptoms scale (NMSS) that 
has been validated (Global Parkinson´s Disease Survey Steering Committee, 2002). His 
assessment suggests that quality of life is strongly correlated with NMSS but only modestly 
with the score of the UPDRS III and IV. This observation has been endorsed by other 
studies. More recently, the highly significant benefit infusion Duodopa has been 
demostrated in prospective studies by sleep scale, PDQ-8 and total score of the NMSS 
(cardiovascular, sleep / fatigue, mood / cognition, perception / hallucination , attention / 
memory, gastrointestinal, urinary, sexual, and miscellaneous (Honig et al., 2009). 
These findings together with the recent publication of PDLIFE study, which shows a 
worsening of motor symptoms and NMS in patients undertreated, demonstrate the 
importance of global symptom control over the control of other focal symptoms (Grosset et 
al., 2007). 
The observation of improvement in important domains of NMSS underscores the 
hypothesis that important aspects of the NMS may in part be related to the pathophysiology 
of dopamine. This finding is consistent with studies suggesting that depression, aspects of 
sleep dysfunction such as insomnia, restless leg syndrome, nocturia, pain, sexual 
dysfunction, apathy, and anhedonia are partly related to dysfunction of the dopaminergic 
system (Remy et al., 2005; Devos, 2009). 
2.3.2 Complications  
The infusion system of Duodopa includes infusion pump systems, internal and external 
connection to the jejunum and percutaneous gastrostomy. Any complications may present 
in any of these levels, the most common are unintentional disconnection of the tube, 
obstruction of the tube kinking or migration intestinal. Other complications related to 
gastrostomy as infection, local inflammation or peritonitis are rare. Complications can also 
occur due to the Duodopa itself such as psychosis, biphasic dyskinesias, behavioral changes 
with impaired impulse control, orthostasis, and hallucinations, usually easily controlled 
(Honig et al., 2009). 
Adverse effects in relation to Duodopa (drowsiness, visual hallucinations, psychotic 
episodes, dizziness, headache) are similar to those seen with conventional levodopa 
www.intechopen.com
Advances in Drug Therapy: Alternative Treatments  
for the Control of Motor Fluctuations and Dyskinesias 
 
111 
(Nyholm et al., 2005). There have been case reports of polyneuropathy of the Guillain Barre 
type (Antonini et al., 2007) and development of vitamin B12 and B6 deficiency 
polyneuropathy (Onofrj et al., 2009). 
2.3.3 Conclusion  
Duodopa can be summarized that is effective and safe, with significant benefit for the 
control of motor and non motor symptoms. Most problems are not serious and generally 
easy to solve, with favorable risk/benefit ratio. Its indication in patients with advanced PD 
with severe motor fluctuations and dyskinesias may represent an alternative to surgery and 
continuous infusion of apomorphine. The candidate selection is not as restrictive as in the 
other two techniques, so that patients which are not optimal for surgery and apomorphine 
can be treated successfully with Duodopa (Devos, 2009; Sánchez-Castañeda et al., 2010). 
But despite clinical benefits, total number of patients treated with infusions is still limited 
due to the complexity of the procedure. 
The general conclusions are: 
1. Infusions provide constant plasma levels preventing the peaks and valleys that are 
typical of the medication orally.  
2. Infusions can reduce dyskinesias and extend the therapeutic window in advanced PD. 
3. Apomorphine is effective in reducing off time but improvement of dyskinesias is 
limited by the need to continue with oral L-dopa in most patients. Its use remains 
limited in time and its discontinuation is mainly due to the development of skin 
reactions. 
4. Experience with continuous infusion of duodenal L-dopa/carbidopa shows that the 
benefit is also related to the quality of life and better control of non-motor symptoms 
such as cardiovascular system, bladder, gastrointestinal function and sleep quality 
3. Behavioral disorders and their relationship with dopaminergic medication 
In recent years interest has focused on behavioral disorders in Parkinson´s Disease due to 
their higher prevalence than in the general population and its relation to dopaminergic 
therapy, primarily to the use of dopamine agonists. It  includes impulse control disorders 
(ICD) such as pathological gambling, buying and compulsive food intake, hypersexuality 
and repetitive stereotyped behaviors-punding devoid of purpose and dopamine 
dysregulation syndrome also known as syndrome of addictive behavior, in which there is a 
progressive, increased and excessive consumption of dopaminergic drugs, higher than 
needed to control the motor symptoms of the disease despite the occurrence of severe 
dyskinesias. It develops a tolerance to the euphoric effect of dopaminergic therapy and often 
produces a state of abstinence because of the reduction or withdrawal of medication in 
addition to motor worsening, complicating the management of this type of addictive 
disorder. 
The impulse control disorder is characterized by an inability to resist an impulse or 
temptation to perform an act that can be harmful to other or to themselves. It is very 
important to identify because it can cause significant distress to patients and caregivers, 
serious financial and socio-familiar consequences. Its key feature is the participation in a 
repetitive and compulsive behavior despite adverse consequences, an impulse of appetite or 
desire before engaging in the problematic behavior and a hedonic quality during the 
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execution of the act. It shares a conceptual resemblance to the drug addiction in which 
patients perform compulsive activity despite adverse consequences (Ceravolo et al., 2010). 
Addictive behavior syndrome is a neuropsychiatric disorder of behavior associated with 
excessive use of dopaminergic drugs, more frequently with levodopa and apomorphine. 
The clinical features met the accepted criteria for addiction: compulsive use of drugs, 
hypomania, impulsivity, withdrawal symptoms such as anxiety and dysphoria. The 
psychiatric features include manic, elation, irritability, psychomotor agitation, paranoia 
towards hospital staff and family.  Complusive acts with stereotyped behaviors frecuently 
occurs in this syndrome. These acts are characterized by an intense fascination for handling 
technical equipment repetitively and continuously or review and classification of common 
objects (Ceravolo et al., 2010). 
The prevalence of these disorders varies according to the series. They are often 
underdiagnosed because not all patients are aware of the problem and they do not relate 
them to the PD. At other times patients are reluctant to admit the existence of these 
disorders. Recently in a large cross-sectional study of 3090 patients with idiopathic PD has 
been described the existence of any impulse control disorder in 13.6%, of which pathological 
gambling 5.0%, compulsive behavior of sex 3.5%, compulsive buying 5.7%, eating disorder 
4.3%. Several disorders are often associated in the same individual 3.9%. This disorder 
occurs more frequently in patients taking AD (17.7%) compared to those who do not take 
(6.9%), finding no significant difference between Pramipexole 17.7% vs Ropinirole 15.5% 
(Weintraub et al., 2010). 
In addition to individual factors, predisposing factors have been identified such as the 
duration of the disease, high doses of medication, especially AD unrelated to any specific 
(class effect) (Ceravolo et al., 2010) but may also occur at low doses, at lower age, at disease 
onset (Voon et al., 2006), the existence of affective disorders (Pontone et al., 2006) and a ICD 
before PD (Weintraub et al., 2006) and the presence of motor complications. However, no 
differences were found in Hoehn and Yahr stage between patients with and without ICD. 
Treatment usually involves the reduction/suspension of AD, adjusting the dose of 
levodopa. If these measures are insufficient alternative pharmacological measures can be 
employed, though less user experience. Thus selective inhibitors of serotonin reuptake have 
proven effective in binge eating and stereotyped behaviors (Wolters et al., 2008). Atypical 
antipsychotics such as quetiapine are useful in pathological gambling and hypersexuality. In 
the latter case can be used antiandrogens such as cyproterone acetate (Klos et al., 2005). 
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